Teva at a decade high, and analysts are convinced there is more room to grow
In Globes' weekly section, we analyzed the performance of prominent Israeli stocks on Wall Street. Wix stock has doubled its value since the June low, driven by the rapid growth of its subsidiary, Base44. Teva reached a decade-high peak thanks to a debt rating upgrade and accelerated FDA approval. Meanwhile, the deal to sell LivePerson is delayed due to a lack of a majority among all shareholders.
On Friday, trading on Wall Street closed with a positive trend, with gains of 0.4%-1% in the leading indices. However, in the summary of the last two trading days and the entire week, the indices recorded declines. Here are the Israeli stocks (and those with ties to Israel) that stood out in trading.
Wix has doubled its value since the last low
Exactly two months ago, Wix stock was trading at a low of just over $40, but since then it has recovered and more than doubled, closing the week at over $82 (recall that earlier this year, the company bought back its own shares for $1.6 billion at a price of $92, a level it has not yet returned to). The market value of the internet company, under the management of Avishai Abrahami, now reaches about $3.4 billion.
Wix, which allows users to build and manage websites, and acquired Base44 in 2025—a company operating in the field of Vibe Coding—was one of the stocks that suffered particularly from the "SaaSpocalypse" (fears regarding the business model of software companies amid AI development). Its stock fell, the company fired about 20% of employees and lowered its annual forecast. It seems the stock found its bottom and has since recovered. In early August, Wix published reports beating forecasts, leading to a 15% rise. The company noted it would continue to invest in Base44's marketing and sales to increase market share, stating that in the second half of 2026, Base44's gross profitability (Non-GAAP) would be about 60%, compared to 0% at the beginning of the year. Last week, Maor Shlomo, who founded and manages Base44, wrote on LinkedIn that the company reached an ARR (annual recurring revenue) of $200 million, 5 months after hitting $100 million.
According to the Wall Street Journal, out of 24 analysts covering Wix, 11 are positive, 12 neutral, and one negative, with an average target price 5% lower than the current Nasdaq price.
Teva stock rose by about 20% in the last month
Teva stock closed on Wednesday at a peak (in dollars) not seen since the beginning of 2017. The stock weakened slightly in the following two trading days but closed the week at a price reflecting a market value of $43.5 billion.
The pharmaceutical company, under the management of Richard Francis, has published several positive reports in recent weeks, helping the stock recover from a period of weakness and leading to a 20% rise over the last month. In late July, the company raised its annual revenue forecast. This month, it reported that Moody's upgraded Teva's debt rating to investment grade, following a similar move by Fitch earlier this year. Another positive development last week was the FDA's acceptance of Teva's request for the approval of Ecopipam, intended for the treatment of children with Tourette syndrome. The review process will be accelerated, with a target decision date at the end of the first quarter of 2027.
As of today, according to Wall Street Journal data, 12 out of 13 analysts covering Teva stock recommend it positively, with one neutral. Their average target price is $42.38, reflecting a 12.3% premium over the current New York Stock Exchange price.
LivePerson: the majority for the sale approval has not yet been achieved
The American software company LivePerson, traded on both Nasdaq and the Tel Aviv Stock Exchange, hoped to achieve the majority required at its shareholders' meeting to approve its sale to SoundHound, but will have to wait a little longer.
LivePerson provides SaaS solutions for managing customer relations. The company, under the management of John Sabino, announced its sale for $43 million last April, after its value plummeted by 99% from its peak. It later announced it would be delisted from the Tel Aviv Stock Exchange on September 7.
The shareholders' meeting convened last Thursday did achieve the required quorum, and preliminary results show that 97% of voters supported the deal. However, a majority of all LivePerson shareholders is required, and the company notes it has not yet been reached, though "we are a few percentage points away." The company extended the voting deadline to September 2. Before the meeting, American consulting firms ISS and Glass Lewis published opinions supporting the deal.
LivePerson has been traded on the local exchange since 2011. During the pandemic, the stock reached a peak with a valuation of $4.7 billion and was part of the TA-35 index. The company enjoyed positive sentiment then as its products allowed businesses to communicate via digital channels. However, this demand was not reflected in LivePerson's results, which continued to lose money and disappoint investors.
